Clinical Trials
3 trialsNCT00811733 2017-05-30
A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia
GlaxoSmithKline
Phase 2 Completed
NCT01536067 2016-06-10
Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia
Roswell Park Cancer Institute
Phase 2 Terminated
NCT01119794 2015-08-26
Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab
Brown University
Phase 2 Terminated